In PDAC models, CAFs have in a mechanism involving TGF-β been demonstrated to upregulate αvβ5 levels in PDAC cells, in turn making them an efficient drug target for the tumor-penetrating iRGD peptide (Hurtado de Mendoza et al. 2021). The gene discussed is TGFB1; the disease is neoplasm.